000130706 001__ 130706
000130706 005__ 20240228143455.0
000130706 0247_ $$2doi$$a10.1118/1.4949003
000130706 0247_ $$2pmid$$apmid:27277043
000130706 0247_ $$2ISSN$$a0094-2405
000130706 0247_ $$2ISSN$$a1522-8541
000130706 0247_ $$2altmetric$$aaltmetric:7560069
000130706 037__ $$aDKFZ-2017-05784
000130706 041__ $$aeng
000130706 082__ $$a610
000130706 1001_ $$0P:(DE-He78)01ddf9bd69d91bd4b1dbef36f9427f36$$aValous, Nektarios$$b0$$eFirst author$$udkfz
000130706 245__ $$aSpatial intratumoral heterogeneity of proliferation in immunohistochemical images of solid tumors.
000130706 260__ $$aNew York, NY$$c2016
000130706 3367_ $$2DRIVER$$aarticle
000130706 3367_ $$2DataCite$$aOutput Types/Journal article
000130706 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524562596_16745
000130706 3367_ $$2BibTeX$$aARTICLE
000130706 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130706 3367_ $$00$$2EndNote$$aJournal Article
000130706 520__ $$aThe interactions of neoplastic cells with each other and the microenvironment are complex. To understand intratumoral heterogeneity, subtle differences should be quantified. Main factors contributing to heterogeneity include the gradient ischemic level within neoplasms, action of microenvironment, mechanisms of intercellular transfer of genetic information, and differential mechanisms of modifications of genetic material/proteins. This may reflect on the expression of biomarkers in the context of prognosis/stratification. Hence, a rigorous approach for assessing the spatial intratumoral heterogeneity of histological biomarker expression with accuracy and reproducibility is required, since patterns in immunohistochemical images can be challenging to identify and describe.A quantitative method that is useful for characterizing complex irregular structures is lacunarity; it is a multiscale technique that exhaustively samples the image, while the decay of its index as a function of window size follows characteristic patterns for different spatial arrangements. In histological images, lacunarity provides a useful measure for the spatial organization of a biomarker when a sampling scheme is employed and relevant features are computed. The proposed approach quantifies the segmented proliferative cells and not the textural content of the histological slide, thus providing a more realistic measure of heterogeneity within the sample space of the tumor region. The aim is to investigate in whole sections of primary pancreatic neuroendocrine neoplasms (pNENs), using whole-slide imaging and image analysis, the spatial intratumoral heterogeneity of Ki-67 immunostains. Unsupervised learning is employed to verify that the approach can partition the tissue sections according to distributional heterogeneity.The architectural complexity of histological images has shown that single measurements are often insufficient. Inhomogeneity of distribution depends not only on percentage content of proliferation phase but also on how the phase fills the space. Lacunarity curves demonstrate variations in the sampled image sections. Since the spatial distribution of proliferation in each case is different, the width of the curves changes too. Image sections that have smaller numerical variations in the computed features correspond to neoplasms with spatially homogeneous proliferation, while larger variations correspond to cases where proliferation shows various degrees of clumping. Grade 1 (uniform/nonuniform: 74%/26%) and grade 3 (uniform: 100%) pNENs demonstrate a more homogeneous proliferation with grade 1 neoplasms being more variant, while grade 2 tumor regions render a more diverse landscape (50%/50%). Hence, some cases show an increased degree of spatial heterogeneity comparing to others with similar grade. Whether this is a sign of different tumor biology and an association with a more benign/malignant clinical course needs to be investigated further. The extent and range of spatial heterogeneity has the potential to be evaluated as a prognostic marker.The association with tumor grade as well as the rationale that the methodology reflects true tumor architecture supports the technical soundness of the method. This reflects a general approach which is relevant to other solid tumors and biomarkers. Drawing upon the merits of computational biomedicine, the approach uncovers salient features for use in future studies of clinical relevance.
000130706 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000130706 588__ $$aDataset connected to CrossRef, PubMed,
000130706 7001_ $$aLahrmann, Bernd$$b1
000130706 7001_ $$aHalama, Niels$$b2
000130706 7001_ $$aBergmann, Frank$$b3
000130706 7001_ $$0P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aJäger, Dirk$$b4$$udkfz
000130706 7001_ $$aGrabe, Niels$$b5
000130706 773__ $$0PERI:(DE-600)1466421-5$$a10.1118/1.4949003$$gVol. 43, no. 6, p. 2936 - 2947$$n6$$p2936 - 2947$$tMedical physics$$v43$$x0094-2405$$y2016
000130706 909CO $$ooai:inrepo02.dkfz.de:130706$$pVDB
000130706 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ddf9bd69d91bd4b1dbef36f9427f36$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130706 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000130706 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000130706 9141_ $$y2016
000130706 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMED PHYS : 2015
000130706 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130706 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130706 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000130706 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000130706 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130706 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130706 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130706 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130706 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000130706 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000130706 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000130706 9201_ $$0I:(DE-He78)G010-20160331$$kG010$$lGeschäftsstelle$$x0
000130706 9201_ $$0I:(DE-He78)D120-20160331$$kD120$$lAngewandte Tumor-Immunität$$x1
000130706 980__ $$ajournal
000130706 980__ $$aVDB
000130706 980__ $$aI:(DE-He78)G010-20160331
000130706 980__ $$aI:(DE-He78)D120-20160331
000130706 980__ $$aUNRESTRICTED